Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
Biliary Atresia, Cholangitis, Anti-Bacterial Agents
About this trial
This is an interventional prevention trial for Biliary Atresia
Eligibility Criteria
Inclusion Criteria: Patients whose age of operation is 14-90 d. Sex and race are not restricted; Patients who are born with gestational age older than 36 weeks; Patients whose body weight before operation > 2 kg; Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University; The type-III BA diagnosis is based on cholangiography or operation; Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported; Patients who are not allergic to postoperative medications; Patients who haven't accepted other antibiotic or probiotic therapy. Exclusion Criteria: Patients with cholestasis of non-BA disease; Patients who have undergone KP at other institutions; Patients whose pathohistological diagnosis is in doubt; Patients who undergo liver transplantation immediately after KP; Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy; Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis; Patients judged by the researchers that they can not comply with the study requirements.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Antibiotics group
Non-antibiotics group
Basic treatment + Prophylactic oral antibiotics
Basic treatment